---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095433"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:10:54.130060+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kyverna Q2 net loss $28.8M; cash $346.2M; RMAT designations for KYV-101

## Summary
- Q2 net loss $28.8M ($0.67 per share) vs $13.1M loss year ago.
- Cash, equivalents & marketable securities $346.2M as of June 30, 2024.
- No severe ICANS or CRS Grade ≥3 in 36 autoimmune patients treated with KYV-101.
- 100% manufacturing success for KYV-101 across 36 patients.
- Received FDA RMAT designations for Stiff-Person Syndrome and Myasthenia Gravis.

## SEC filing metadata
- accession: 0000950170-24-095433
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000095017024095433/0000950170-24-095433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000095017024095433/kytx-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095433
- JSON: https://secwatch.observer/filing/0000950170-24-095433.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095433.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.